Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction A Meta-Analysis

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction A Meta-Analysis
	Jiang, L; Yang, KH; Guan, QL; Chen, Y; Zhao, P; Tian, JH; Yang, KH (reprint author), Lanzhou Univ, Hosp 1, 1 Dong Gang Rd, Lanzhou 730000, Gansu, Peoples R China.
刊名	JOURNAL OF CLINICAL GASTROENTEROLOGY
	2015-05-06
卷号	49 期号:5 页码:387-394
关键词	neoadjuvant chemotherapy gastroesophageal junction cancer gastric cancer meta-analysis
ISSN号	0192-0790
文献子类	Article
英文摘要	Background: The objective of the present meta-analysis was to estimate the magnitude of survival benefits of neoadjuvant chemotherapy (NAT) in resectable cancer of the gastric and gastroesophageal junction. Materials and Methods: We searched PubMed, Embase, the Cochrane Library, ISI Web of Knowledge, Chinese biomedical literature database, Chinese Scientific Journals full-text database of retrieved articles from their inception to 2013. Two reviewers independently retrieved study and data extraction of included studies. Results regarding the overall survival and progression-free survival in the meta-analysis were expressed as hazard ratios (HRs) with 95% confidence intervals (CI). Results: Twelve randomized control trials (n= 1755) were eligible for final meta-analysis. NAT was associated with a statistically significant benefit in terms of overall survival (HR= 0.72; 95% CI, 0.56-0.93, P= 0.01), progression-free survival (HR= 0.73; 95% CI, 0.62-0.87, P= 0.0003), 5-year survival rate [ relative risk (RR)= 1.36; 95% CI, 1.10-1.67, P= 0.0004], and curative resection rate (RR= 1.11; 95% CI, 1.03-1.20, P= 0.009). Five-year survival rate increased from 30% to 42% with NAT. No significant difference with regards to overall postoperative complications rate (RR= 1.08; 95% CI, 0.92-1.27, P= 0.28) was found between 2 groups. Conclusion: There is convincing evidence for a survival benefit of NAT over surgery alone in patient with cancer of the gastric and gastroesophageal junction.
学科主题	Gastroenterology & Hepatology
出版地	PHILADELPHIA
资助项目	中央高校基本科研业务费专项资金
项目编号	Fundamental Research Funds for the Central Universities [lzujbky-2013-160]
语种	英语
WOS记录号	WOS:000352791500006
资助机构	LZU
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/178576]
专题	第一临床医学院_期刊论文
通讯作者	Yang, KH (reprint author), Lanzhou Univ, Hosp 1, 1 Dong Gang Rd, Lanzhou 730000, Gansu, Peoples R China.
推荐引用方式 GB/T 7714	Jiang, L,Yang, KH,Guan, QL,et al. Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction A Meta-Analysis[J]. JOURNAL OF CLINICAL GASTROENTEROLOGY,2015,49(5):387-394.
APA	Jiang, L.,Yang, KH.,Guan, QL.,Chen, Y.,Zhao, P.,...&Yang, KH .(2015).Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction A Meta-Analysis.JOURNAL OF CLINICAL GASTROENTEROLOGY,49(5),387-394.
MLA	Jiang, L,et al."Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction A Meta-Analysis".JOURNAL OF CLINICAL GASTROENTEROLOGY 49.5(2015):387-394.